Name: Évaluation d’un modèle de coloproctite ulcéreuse-cancer colorectal (UC-CRC) et efficacité de la décoction de Liujunzi (LJZD)
Uploaded: 2023-10-13T12:50:00
Description: Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

evaluation of an ulcerative coloproctitis-colorectal cancer (uc-crc) model and efficacy of liujunzi decoction (ljzd)

Décoction de Liujunzi : un traitement efficace pour la prévention de l’UC-CRC

Colorectal cancer (CRC) is a common gastrointestinal malignancy, the third most common malignancy, and the second most common cause of death in the world, accounting for 10% of the global cancer incidence and 9.4% of the total cancer-related death1,2. Genetic factors, chronic inflammation, high-fat diet, diabetes, and abnormal intestinal flora are risk factors for CRC3,4. Among them, inflammatory bowel disease, especially ulcerative coloproctitis (UC), is a clear risk factor for CRC5,6. UC-associated CRC (UC-CRC) is a transition process of inflammation, atypical hyperplasia, and cancer based on chronic inflammation of the colorectum, which is different from the typical adenoma-adenocarcinoma development model of CRC7,8. Compared with the general population, the risk of CRC is approximately 10-40 times higher in patients with inflammatory bowel disease9.
Currently, surgery is still the standard treatment for CRC, and depending on the location and stage of the tumor, radiation therapy, systemic drug therapy, or a combination of both are possible10. Although these traditional treatment modalities have made great progress, due to the high heterogeneity and recurrence rate of CRC, the prognosis is poor, and the treatment effect is not ideal11,12. Therefore, early detection, early diagnosis, and comprehensive treatment are key to improving the survival rate of CRC patients, and it is particularly important to pay attention to the transformation of UC to CRC. Over the years, traditional Chinese medicine (TCM) has attracted much attention in the treatment of UC-CRC or chronic gastritis due to its limited side effects and significant efficacy. Based on dialectical treatment, famous Chinese medicine practitioners of various generations have created a large number of classic prescriptions, such as Huangqi Jianzhong decoction13, Sijunzi decoction14, and Sishen pill15.
Liujunzi decoction (LJZD) originated from the works of Yi Xue Zheng Zhuan compiled in the Ming Dynasty and is a classic prescription in TCM16. As shown in Table 1, LJZD consists of six traditional herbs, including Codonopsis pilosula (Franch.) Nannf. (Dangshen), Poria cocos (Schw.) Wolf (Fuling), Atractylodes macrocephala Koidz. (Baizhu), Glycyrrhiza uralensis Fisch. (Gancao), Citrus reticulata Blanco (Chenpi) and Pinellia ternata (Thunb.) Breit (Banxia), which has the effect of replenishing qi and strengthening the spleen, drying dampness, and resolving phlegm. In modern clinical practice, it is often used to treat chronic gastritis, gastric ulcers, and duodenal ulcers. Modern pharmacological research has shown that LJZD and modified LJZD have high application value in the adjuvant treatment of UC and digestive tract cancer17,18,19.
At present, there are many ways to construct UC-CRC mouse models, but the azoxymethane (AOM)/dextran sulfate sodium (DSS) induced mouse model is the most widely used UC-CRC model; the clinical symptoms, morphological, and pathological observations have proved that the model is very similar to human UC-CRC20,21. The basic principle is to first induce carcinogenesis with chemical carcinogen AOM and then continuously expose mice to the inflammatory stimulation environment of DSS to simulate the continuous damage and repair of intestinal mucosal epithelium, thereby constructing a UC-CRC mouse model22. The aim of this study is to establish a mouse model of UC-CRC by intraperitoneal injection of AOM and cyclic stimulation of DSS in the short term and to evaluate the effect of the drug and the molecular mechanism of LJZD on UC-CRC in order to provide a scientific basis for the treatment of UC-CRC.

Pleins feux sur l’auteur : La décoction de liujunzi comme traitement traditionnel chinois du cancer de la coloproctite

Établissement d’un modèle de cancer de la coloproctite chez la souris et évaluation de l’effet thérapeutique de la médecine chinoise

This study was on the prevention and treatment of coloproctitis cancer with traditional Chinese medicine. We aim to establish a mouse model for coloproctitis cancer and evaluate traditional Chinese medicine indicators. We confirmed that the Chinese medicine Liujunzi decoction is a effective treatment for coloproctitis cancer prevention.In the future, we will work to identify more sensitive biomarkers for colon and rectal cancer and screen Liujunzi decoction for therapeutic targets.

Watch this Scientific Journal Video about Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer UC-CRC Model and Efficacy of Liujunzi Decoction LJZD at JoVE.com

Évaluation d’un modèle de coloproctite ulcéreuse-cancer colorectal (UC-CRC) et efficacité de la décoction de Liujunzi (LJZD)

Pour commencer, établissez le modèle murin UC-CRC et administrez la solution préparée de LJZD et de 5-ASA aux groupes respectifs. Après le traitement médicamenteux, surveillez quotidiennement le poids des souris depuis le début de l’alimentation adaptative jusqu’à la fin du traitement médicamenteux. Observez et documentez avec diligence la consistance fécale de chaque souris expérimentale, en la classant comme normale, selles molles ou diarrhée aqueuse.Documentez soigneusement tout saignement fécal observé chez les animaux de laboratoire, en le classant en trois catégories : aucun saignement, saignement minimal ou sang visible dans les selles. Pour séparer le tissu colorectal, maintenez les souris euthanasiées dans un environnement anatomique cryogénique. Fixez les souris en position couchée.À l’aide de ciseaux, coupez les poils abdominaux inférieurs et stérilisez la zone avec de l’éthanol. À l’aide d’une pince à paupières, saisissez doucement le point d’intersection entre les deux racines de la cuisse et la ligne médiane abdominale. Utilisez ensuite des ciseaux pour créer une incision transversale d’un à 1,5 centimètre de long.Effectuez une incision longitudinale le long de la ligne médiane de l’abdomen, en partant du point médian de l’incision transversale jusqu’au processus xiphoïde. Détachez soigneusement les tissus péri-colorectaux dans le sens de l’anus, en séparant le colorectum des tissus environnants. Écartez doucement la peau abdominale pour exposer complètement le colorectum.À l’aide d’une pince à paupières, extrayez le colorectum de la cavité abdominale et sectionnez-le de l’anus au caecum Conservez les tissus colorectaux collectés dans une solution saline à quatre degrés Celsius. Le groupe modèle UC-CRC a eu une perte de poids significative par rapport au groupe témoin, qui a été soulagée par le traitement LJZD.Le traitement par LJZD a amélioré l’indice d’activité de la maladie par rapport au groupe modèle UC-CRC.

Research

JoVE Journal

Medicine

Evaluation of an Ulcerative Coloproctitis-Colorectal Cancer (UC-CRC) Model and Efficacy of Liujunzi Decoction (LJZD)

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Colorectal cancer (CRC) is a common malignancy of the digestive system and has become the third most common malignancy worldwide and the second leading ...